Tempus AI, Inc. Class A (TEM)
NASDAQ:TEM
TEM Stock Chart & Stats
$42.94
-$0.17(-0.45%)
At close: 4:00 PM EST
$42.94
-$0.17(-0.45%)
Day’s Range― - ―
52-Week Range$39.01 - $104.32
Previous CloseN/A
Volume1.41M
Average Volume (3M)4.48M
Market Cap
$7.68B
Enterprise Value$7.67B
Total Cash (Recent Filing)$755.00M
Total Debt (Recent Filing)$815.71M
Price to Earnings (P/E)―
Beta2.96
Next Earnings
May 12, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding173,729,900
10 Day Avg. Volume4,002,712
30 Day Avg. Volume4,479,229
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)20.94
Price to Sales (P/S)8.09
P/FCF Ratio-43.03
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue6.03
Enterprise Value/Gross Profit8.66
Enterprise Value/Ebitda-34.50
Forecast
1Y Price Target
$76.00Price Target Upside76.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)-0.64
Revenue Forecast (FY)$1.59B
Bulls Say, Bears Say
Bulls Say
AI And Data LeadershipDevelopment of a foundation AI model, a notable deal with Merck, and large curated multimodal datasets position the company as an AI leader and could translate strong pharma demand into sustained data and applications contracts.
Diagnostics Product MomentumMigration to newer diagnostic platforms and expansion of minimal residual disease testing support expectations for higher testing volumes and improved per-test pricing, offering upside to diagnostic revenue.
Strategic CollaborationsAn expanded multi-year collaboration with a major pharmaceutical company enables use of Tempus' de-identified data and Lens platform to accelerate biomarker discovery and candidate therapy development, supporting potential multi-year data revenue growth.
Bears Say
Competition And Contract RiskIntense competition in genomics and multimodal dataset generation, plus investor concerns about contract renewals and pricing pressure, may constrain revenue growth and valuation upside.
Profitability And Operating ExpenseHigher planned operating expenses combined with ongoing net losses increase margin pressure and raise uncertainty about the timing of sustained adjusted profitability.
Reimbursement RiskEarly-stage progress on reimbursement introduces uncertainty around revenue realization for genomic tests and could delay expected improvements in per-test pricing.
Tempus AI, Inc. Class A News
TEM FAQ
What was Tempus AI, Inc. Class A’s price range in the past 12 months?
Tempus AI, Inc. Class A lowest stock price was $39.01 and its highest was $104.32 in the past 12 months.
What is Tempus AI, Inc. Class A’s market cap?
Tempus AI, Inc. Class A’s market cap is $7.68B.
When is Tempus AI, Inc. Class A’s upcoming earnings report date?
Tempus AI, Inc. Class A’s upcoming earnings report date is May 12, 2026 which is in 30 days.
How were Tempus AI, Inc. Class A’s earnings last quarter?
Tempus AI, Inc. Class A released its earnings results on Feb 24, 2026. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of -$0.033 by -$0.007.
Is Tempus AI, Inc. Class A overvalued?
According to Wall Street analysts Tempus AI, Inc. Class A’s price is currently Undervalued.
Does Tempus AI, Inc. Class A pay dividends?
Tempus AI, Inc. Class A does not currently pay dividends.
What is Tempus AI, Inc. Class A’s EPS estimate?
Tempus AI, Inc. Class A’s EPS estimate is -0.27.
How many shares outstanding does Tempus AI, Inc. Class A have?
Tempus AI, Inc. Class A has 173,729,900 shares outstanding.
What happened to Tempus AI, Inc. Class A’s price movement after its last earnings report?
Tempus AI, Inc. Class A reported an EPS of -$0.04 in its last earnings report, missing expectations of -$0.033. Following the earnings report the stock price went down -7.317%.
Which hedge fund is a major shareholder of Tempus AI, Inc. Class A?
Currently, no hedge funds are holding shares in TEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tempus AI, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$76.00 (76.99% Upside)
$76.00 (76.99% Upside)
Blogger Sentiment
Bullish
TEM Sentiment 76%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 233.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.57%
12-Months-Change
Fundamentals
Return on Equity
-59.95%
Trailing 12-Months
Asset Growth
145.63%
Trailing 12-Months
Company Description
Tempus AI, Inc. Class A
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
TEM Company Deck
TEM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized robust multi-year growth drivers: strong diagnostic unit growth (Oncology +29%, MRD +56% Q/Q), accelerating data business with >$1.1B in TCV and 126% net revenue retention, positive 2026 guidance ($1.59B) and a path to higher ASPs and adjusted EBITDA. Key near-term constraints are reimbursement gating for MRD, moderation and lumpiness in Hereditary growth, and one-time impacts to some reported data growth figures. Overall, the positive revenue, contract backlog, AI/foundation-model progress, and strong customer retention materially outweigh the execution and reimbursement risks highlighted.View all TEM earnings summariesTEM Stock 12 Month Forecast
Average Price Target
$76.00
▲(76.99% Upside)
Technical Analysis
Ownership Overview
22.93% Insiders
8.88% Mutual Funds
27.24% Other Institutional Investors
25.92% Public Companies and Individual Investors